Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 403

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 403
---
 to which, subject to the satisfaction or waiver of the conditions set forth in the HCRX Agreement, Kineta will sell to HCRX all of Kineta’s rights, title and interest in and to the Partnered Programs, for a purchase price of $1.00 in cash and the right to receive 72.5% or 45%, as applicable, of any milestone or royalty payments payable to Kineta pursuant to the Partnered Programs for a period not to exceed six years.

<div align='center'>**F-148

KINETA, INC.

Notes to Consolidated Financial Statements**</div>

**GigaGen

VISTA Agreement Third Amendment

On January 29, 2025, Kineta and GigaGen entered into the Third Amendment to Option and License Agreement (the “Third Amendment to VISTA Agreement”) to, among other things, amend the development and regulatory milestone payments under the VISTA Agreement. Pursuant to the Third Amendment to VISTA Agreement, GigaGen is eligible to receive approximately $20.3 million in development and regulatory milestone payments, including payments previously paid by Kineta.

CD27 Asset Transfer

GigaGen and Kineta entered into a Termination and Mutual Release Agreement, effective January 29, 2025, to terminate their existing CD27 Agreement. The termination is mutually agreed upon and is not due to any fault or breach by either party. GigaGen waived all accrued fees amounting to $180,000 and any future payments from Kineta. Kineta assigned all rights to its sole and joint inventions and patents related to the CD27 program back to GigaGen and transferred all related data and regulatory filings. Both parties released each other from any claims related to the CD27 Agreement and agreed to maintain confidentiality and cooperate in perfecting the transfer of intellectual property.**

<div align='center'>F-149</div>

KINETA, INC. Condensed Consolidated Balance Sheets (in thousands) (Unaudited)

| Assets                                                                                                                                                                                                         
 Current assets:                                                                                                                                                                                                |     | March 31, 
 2025      |          |   |     | December 31, 
 2024         |          |   |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:----------|---------:|:--|:----|:-------------|---------:|:--|
| Cash                                                                                                                                                                                                           |     | $         |      304 |   |     | $            |      634 |   |
| Restricted cash                                                                                                                                                                                                |